New EORTC 2129-BCG TREAT ctDNA study on Early-Stage Breast Cancer in collaboration with MENARINI Group

EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn,

“On Breast Cancer Awareness Month, we are excited to share the launch of the new EORTC 2129-BCG TREAT ctDNA study on Early-Stage Breast Cancer in collaboration with MENARINI Group.

The trial is expected to screen more than 1900 early-stage breast cancer patients at 120+ sites in 12 European countries, commencing in Q4 2023.

The study will evaluate whether elacestrant can delay the occurrence of metastasis or death compared to standard adjuvant endocrine therapy in early-stage ER+/HER2-breast cancer patients with late ctDNA-relapse.”

To read the article click here.
Source: EORTC – European Organisation for Research and Treatment of Cancer/LinkedIn.